Switching from allopurinol to febuxostat: Efficacy and tolerability in hemodialysis patients

被引：8
作者：
Mitsuboshi S. [1 ]
Yamada H. [1 ]
Nagai K. [1 ]
Okajima H. [2 ]
机构：
[1] Department of Pharmacy, Kaetsu Hospital, 1459-1 Higashikanazawa, Akiha-ku, Niigata-shi, Niigata
[2] Department of Internal Medicine, Kaetsu Hospital, 1459-1 Higashikanazawa, Akiha-ku, Niigata-shi, Niigata
来源：
Journal of Pharmaceutical Health Care and Sciences | / 1卷 / 1期
关键词：
Allopurinol; Febuxostat; Hemodialysis; Uric acid;
D O I：
10.1186/s40780-015-0028-1
中图分类号：
学科分类号：
摘要：
Background: Febuxostat is a novel xanthine oxidase inhibitor. However, few studies have examined the long-term efficacy and tolerability of febuxostat after switching from allopurinol in hemodialysis (HD) patients. Therefore, the present study evaluated the long-term efficacy and tolerability of febuxostat in HD patients after switching from allopurinol. Findings: We monitored the levels of hemoglobin, hematocrit, platelet count, blood urea nitrogen, serum creatinine, serum sodium, serum potassium, serum chloride, serum calcium, serum inorganic phosphorus, aspartate transaminase, alanine aminotransferase, alkaline phosphatase, lactate dehydrogenase, and total protein that were considered overall as a tolerability index, while the serum uric acid (UA) level was considered an index of efficacy. All values were measured at baseline and at 1, 6, 12, and 16 months after the switch to febuxostat therapy. All subjects switched from allopurinol (100 mg/day) to febuxostat (10 mg/day) in August 2013. Clinical laboratory data were collected at baseline in July 2013 until December 2014. Nine patients were included in the study analysis. Results showed that clinical laboratory data at baseline versus those at 16 months were not significantly different. Serum UA levels, which represented the efficacy index, were significantly different between the baseline level (6.8 ± 1.4) and those at 1, 6, 12, and 16 months (5.2 ± 1.1, 5.1 ± 1.1, 4.6 ± 0.9, and 5.4 ± 1.8 mg/dL, respectively; all p < 0.05). Conclusion: Switching from allopurinol to febuxostat in HD patients reduced serum UA levels, with no changes in other clinical laboratory data in the long term. © 2015 Mitsuboshi et al.
引用
收藏
相关论文
共 15 条
  • [11] Mayer M.D., Khosravan R., Vernillet L., Wu J.T., Joseph-Ridge N., Mulford D.J., Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment, Am J Ther, 12, pp. 22-34, (2005)
  • [12] Shoji A., Yamanaka H., Kamatani N., A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy, Arthritis Rheum, 51, pp. 321-325, (2004)
  • [13] Wurzner G., Gerster J.C., Chiolero A., Maillard M., Fallab-Stubi C.L., Brunner H.R., Et al., Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout, Hypertens, 19, pp. 1855-1860, (2001)
  • [14] Garg J.P., Chasan-Taber S., Blair A., Plone M., Bommer J., Raggi P., Et al., Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial, Arthritis Rheum, 52, pp. 290-295, (2005)
  • [15] Latif W., Karaboyas A., Tong L., Winchester J.F., Arrington C.J., Pisoni R.L., Et al., Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population, Clin J Am Soc Nephrol, 6, pp. 2470-2477, (2011)
12